Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
GE Healthcare CEO John Flannery is taking over from Jeff Immelt as head of GE and replacing Flannery is Kieran Murphy. Current GE CFO Jeff Bornstein has also been promoted to vice-chair.
HeartFlow Inc. has named device industry veteran Michael Buck executive VP and chief commercial officer.
Health-care consulting firm Avalere Health has tapped Tom Kraus, previously chief of staff at US FDA, and Nancy Beck, who served as a program director of the Reagan-Udall Foundation at the agency, to work on regulatory and commercialization issues at Avalere.
Oxford Immunotec has appointed Karen Koski as its head of strategy and investor relations. Koski joins the company as it prepares to launch this year two new tests from its T-spot platform.
After nearly nine years, MedTech Europe's John Brennan is leaving the medical device and diagnostics trade association. This is a particularly critical time for the industry body and its members, so what has tempted him away at this specific juncture?
Sandra Peterson, Johnson & Johnson group worldwide chair, will take on leadership of the company’s hospital medical device business on June 1 when Gary Pruden, worldwide chair of medical devices, retires.
Jing Xie has moved from Zimmer Biomet to the Medical Device Innovation Consortium to serve as the public-private partnership's first VP of clinical affairs.
UK imaging and radiotherapy trade association AXREM has named Peter Harrison, managing director of Siemens Healthcare in the UK, as chairman for 2017-18.
SmartInhaler developer Adherium has appointed the co-founder of MicroDose Therapeutx to head up its European base in Amsterdam, Netherlands.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.